Humana Inc. logo

Humana Inc. (HUM)

Market Open
3 Mar, 18:10
NYSE NYSE
$
181. 64
-5.64
-3.01%
$
21B Market Cap
19.08 P/E Ratio
3.54% Div Yield
1,010,736 Volume
28.29 Eps
$ 187.28
Previous Close
Day Range
176.71 184.85
Year Range
169.61 315.35
Want to track HUM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
HUM earnings report is expected in 56 days (28 Apr 2026)
Countdown to Humana (HUM) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Countdown to Humana (HUM) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Humana (HUM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Zacks | 4 months ago
Humana (HUM) Expected to Beat Earnings Estimates: Should You Buy?

Humana (HUM) Expected to Beat Earnings Estimates: Should You Buy?

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 4 months ago
Here's Why Humana (HUM) is a Strong Value Stock

Here's Why Humana (HUM) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 4 months ago
Humana: Up 13% In A Week, Will HUM Stock Rally Continue?

Humana: Up 13% In A Week, Will HUM Stock Rally Continue?

Humana (NYSE: HUM) is currently riding a wave of positive momentum. The stock has been on a five-day continuous winning streak, delivering cumulative gains of 13% and adding approximately $4.0 billion in value.

Forbes | 4 months ago
Humana loses challenge to 2025 Medicare Advantage ratings

Humana loses challenge to 2025 Medicare Advantage ratings

A U.S. judge on Tuesday rejected Humana's bid to challenge the Centers for Medicare & Medicaid Services' 2025 ratings for its Medicare Advantage programs, which could cost the company millions in bonus payments from the government.

Reuters | 4 months ago
Why Humana (HUM) is a Top Value Stock for the Long-Term

Why Humana (HUM) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 4 months ago
Humana provides a peak into its Medicare Advantage plan ratings, and the stock jumps

Humana provides a peak into its Medicare Advantage plan ratings, and the stock jumps

Humana's stock spiked after the health insurer disclosed some findings from the government's Star Ratings for its 2026 Medicare Advantage plans.

Marketwatch | 5 months ago
Humana Benefits From Rising Premiums Amid High Benefit Ratio

Humana Benefits From Rising Premiums Amid High Benefit Ratio

HUM gains from rising premiums, Medicare growth and CenterWell expansion, but faces pressure from high benefit ratios and costs.

Zacks | 5 months ago
Is Humana (HUM) Stock Undervalued Right Now?

Is Humana (HUM) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 5 months ago
Why Is Humana (HUM) Up 19.2% Since Last Earnings Report?

Why Is Humana (HUM) Up 19.2% Since Last Earnings Report?

Humana (HUM) reported earnings 30 days ago. What's next for the stock?

Zacks | 6 months ago
Here's Why Humana (HUM) is a Strong Momentum Stock

Here's Why Humana (HUM) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 6 months ago
Humana, DrFirst Ties Up to Boost Statin Use in High-Risk Patients

Humana, DrFirst Ties Up to Boost Statin Use in High-Risk Patients

HUM partners with DrFirst to increase statin use in high-risk patients with diabetes and cardiovascular disease, aiming to close care gaps.

Zacks | 6 months ago
Loading...
Load More